Latest Articles
-
Consider Buying Merck Over Johnson & Johnson’s Stock
Johnson & Johnson’s stock (NYSE:JNJ) has gained 38% since the March 23 lows of this year, while Merck’s stock (NYSE:MRK) has slightly underperformed and gained 30% of its value. The lockdown in various parts of the world has had a nega...
-
Eli Lilly Stock Is Trending But Is Merck Better?
Merck’s stock (NYSE:MRK) has declined by close to 10% since early February after the WHO declared the coronavirus a global health emergency, while Eli Lilly stock (NYSE:LLY) has fared much better and gained 15%. The lockdown in various par...
-
Merck Over Roche For 25% Gains?
Two pharmaceutical giants – Merck (NYSE:MRK) and Roche (OTCMKTS:RHHBY) – have seen their stock price grow over 20% since March 23 lows, significantly underperforming the broader markets, which rallied over 40% through June 5 from the ...
-
Merck’s Stock Headed To $100?
Merck’s stock (NYSE:MRK) has underperformed the broader markets as well as some of its peers over the last few weeks. While Merck’s stock grew 20% since the recent lows of March 23, the S&P 500 gained 26%. Looking at other pharmac...
-
After Allergan Acquisition Is AbbVie A Better Buy Compared To Merck?
The pharmaceutical companies have not been immune to the current coronavirus crisis, although they have fared much better than the broader markets. While Merck’s (NYSE:MRK) stock has declined 9% since early February, after the WHO declared ...
-
Despite Outperforming The Broader Markets, Merck Appears To Be Oversold At $80
Merck (NYSE:MRK) stock declined 10% from $90 levels in the beginning of this year to $80 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Merck’s stock has marginally outperformed the broader markets, we believe...
-
Can Merck’s Keytruda Be Worth $200 Billion?
Keytruda is to Merck (NYSE:MRK), the way iPhone is to Apple. From nothing, it garnered >$11 billion in sales over the last 5 years, and it is now a leading oncology drug. In this note, Can Merck’s Keytruda Be Worth $200 Billion By 2025 ?, ...
-
35% Upside For Merck’s Stock?
Merck (NYSE:MRK) could see a 35% upside from the current levels, based on our price estimate of $96, which is based on expected 2020 earnings of $5.85 on an adjusted basis, and a price to earnings multiple of 16.4x. Merck’s stock has seen ...
-
How Merck Gets To $51 Billion: Oncology or Vaccines?
Merck (NYSE:MRK) revenue grew from $39.8 billion in 2016 to $46.8 billion in 2019, and it is estimated to top $51.5 billion in 2020, primarily driven by its oncology drug, Keytruda, according to our estimates. The company’s oncology drugs will a...
-
Is Merck A Good Buy At Current Levels?
Going by trends seen during the 2008 slowdown, Merck (NYSE: MRK) appears to be a good buy at the current levels of under $75, and it could outperform the broader S&P 500 index, when the coronavirus and oil price war crisis winds down. We saw...
-
Merck Q4 Earnings Preview: Can MRK Beat Average Consensus Earnings?
Merck is slated to release its Q4 and full-year 2019 results on February 5, 2020. We don’t expect the company to beat, but rather meet, the average consensus EPS of $5.17. For full year 2019, Trefis estimates that the company will report: ...
-
How Much Revenue Does Merck Generate From The United States?
Merck (NYSE:MRK) generates its revenue primarily from sales of pharmaceutical products. The company generated $18 billion in sales in the United States, accounting for over 40% of its total revenue in 2018. This figure has been on a decline and ...
-
What’s Fueling Merck’s Stock Price Growth?
Merck’s (NYSE:MRK) stock price grew over 50% from around $56 levels in 2017 to around $84 in 2019, primarily driven by revenue growth and expansion of the P/E multiple. Merck’s stock price growth was higher than <10% growth seen f...
-
Merck’s $3 Billion Drug Jumped To 4x Growth Over Previous Year
Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, orophary...
-
Merck’s Leadership In HPV Vaccines Market
Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, orophary...
